Life Sciences

  • November 05, 2026

    J&J Should Pay $60M For Talc User's Cancer, Jury Told

    Johnson & Johnson should pay $60 million for the death of a woman who developed mesothelioma alongside her heart problems after using talc products allegedly contaminated with asbestos, counsel for her family told a Massachusetts state jury during closing arguments Thursday.

  • November 05, 2026

    In Moderna Row, Fed. Circ. Mulls What's 'For The Government'

    The Federal Circuit on Thursday took a critical look at a lower court's decision concluding that Moderna had to face Arbutus' infringement claims over its COVID-19 vaccines, with one judge repeatedly asking why Moderna's vaccine efforts weren't "for the government" within the meaning of a statutory shield for contractors.

  • November 05, 2026

    5 Firms Guide Brains Bioceutical's $750M SPAC Merger

    Cannabinoid life sciences and pharmaceutical company Brains Bioceutical Corp. on Thursday unveiled plans to go public by merging with special purpose acquisition company Armada Acquisition Corp. III in a deal that values it at roughly $750 million and that was built by five law firms.

  • November 05, 2026

    Invitae Privacy Suit Must Get OK From NJ Bankruptcy Judge

    A New Jersey bankruptcy judge said Thursday he will need to see more evidence to resolve an "ambiguity" over whether class action privacy claims against genetic testing company Invitae Corp. belong in his court.

  • November 05, 2026

    Ex-Sales Leader Violated 'Secrecy' Pact, J&J Ortho Unit Says

    Johnson & Johnson's orthopedic device unit DePuy Synthes alleged in New Jersey federal court that a former national sales leader's move to a rival violates several of his employment agreements, asking the court to order expedited discovery and block him from contacting any of its customers.

  • November 05, 2026

    Albertsons, Safeway Owe Wash. $900M Over Opioid Diversion

    Albertsons and its Safeway subsidiary must pay $900 million for helping fuel Washington state's overdose crisis by failing for years to prevent the diversion of opioid drugs, a Seattle judge ruled Thursday, finding that the pharmacy chains regularly failed to follow their own policies aimed at ensuring prescriptions were legitimate.

  • November 05, 2026

    Ropes & Gray-Led Pharma Biz Offers $541M For Swedish Rival

    U.S. biopharma company ANI said Thursday it has offered to acquire Swedish pharmaceutical company Egetis for up to approximately 5.3 billion Swedish kronor ($541 million) to gain access to a newly approved drug.

  • November 04, 2026

    Pharmacy Worker Says Dosage Machine Cut Off Fingertip

    A pharmacy worker suffered a "traumatic" finger amputation when a machine that dispenses liquid medication caught her index finger and ripped part of it off, according to a lawsuit in Pennsylvania state court that accuses medical device manufacturer Precision Products Group Inc. of defective design.

  • November 04, 2026

    Anti-Pot Group Eyes New Repeal Pushes After Mass. Loss

    After Election Day, anti-cannabis activists are pledging to bring repeal efforts to other states despite a decisive defeat in Massachusetts, while pro-cannabis industry and consumer-focused groups say they hope to work with a Democrat-controlled Congress to secure federal reform.

  • November 04, 2026

    2nd Circ. Told To Not Expand Antitrust Patent Fraud Standing

    A pharmaceutical industry trade group has backed Bristol-Myers Squibb and its Celgene subsidiary in the Second Circuit, warning that health plans asking the appeals court to reinstate a proposed class action against the companies are seeking to expand who can bring antitrust cases alleging fraudulently obtained patents.

  • November 04, 2026

    Gene Firm Sues Pentagon Over 'Chinese Military' Label

    A Chinese genetic sequencing company has sued the Pentagon, saying it was wrongly labeled a "Chinese military company" without a warning or a chance to respond.

  • November 04, 2026

    AGs Say Taro's $200M MDL Deal Doesn't Bar Their Claims

    Dozens of state attorneys general urged a Connecticut federal judge Tuesday not to let Taro Pharmaceuticals block a swath of their price-fixing claims with a $200 million settlement it struck with plaintiffs in separate multidistrict litigation, arguing the claims and plaintiffs are too separate to bind one another.

  • November 04, 2026

    Walgreens Seeks Sanctions In Investors' Pharma Growth Suit

    Walgreens has asked an Illinois federal judge to sanction investors and their attorneys in a securities fraud class action, arguing they continued to falsely attribute statements about the company's plans to open hundreds of clinics to a former executive even after a recording showed his statement was taken out of context.

  • November 04, 2026

    CVS To Split In 2, Unraveling Decade-Old Megamerger

    CVS Health said Wednesday that it plans to split into two independent, publicly traded companies, separating its Aetna- and Caremark-led healthcare businesses from its 9,000 retail pharmacy locations, reversing its nearly decade-old combination of the businesses.

  • November 03, 2026

    Va., Mo. Voters Deliver Wins For Abortion Rights

    Supporters of abortion access won key victories Tuesday in Virginia and Missouri as voters across the country took up healthcare measures that will shape state laws on reproductive and gender-affirming care, according to partial, unofficial returns.

  • November 03, 2026

    Feds Dropping Charges Against Harvard Researcher

    The government is dropping charges against a Harvard researcher and Russian national who was found with preserved clawed frog embryo samples at Boston's Logan International Airport last year, according to a filing Tuesday evening.

  • November 03, 2026

    Birth Control Clip Maker Must Face Injury Case Trial

    Medical device importer and distributor CooperSurgical Inc. failed to secure quick wins on several claims in a bellwether product liability case alleging injuries from Filshie Clip birth control devices, with a Connecticut state judge finding that federal law does not preempt six women's failure-to-warn allegations.

  • November 03, 2026

    Youth File Fresh Appeal In Colo. Hospital Gender Care Suit

    Transgender youth patients of Children's Hospital Colorado have brought yet another challenge to a judge's discharge of their contempt citation against the hospital for not resuming providing them medical gender-affirming care, this time asking the Colorado Court of Appeals to weigh in on whether the hospital complied with an injunction.

  • November 03, 2026

    Blood Vessel Maker Strikes $9M Deal To End Investor Action

    Biotechnology company Humacyte Inc. and a proposed class of investors have reached a $9 million deal to end claims that the company failed to disclose quality assurance issues at its manufacturing facilities that allegedly delayed regulatory review for its bioengineered blood vessel product candidate, leading to stock price declines.

  • November 03, 2026

    3M Inks $7.35B Deal To Settle Most PFAS Foam Claims

    3M Co. announced Tuesday that it will pay up to $7.35 billion over nine years to resolve nearly all personal injury claims related to PFAS "forever chemicals" in firefighting foam.

  • November 03, 2026

    PBM Says Fla. Collusion Suit Belongs In Federal Court

    A pharmacy benefit manager accused by Florida's attorney general of colluding with a competitor to fix prescription drug reimbursement rates for pharmacies removed the state's suit to federal court, citing its work for federal and military employees.

  • November 03, 2026

    Fed. Circ. Unsure How Judge Messed Up Drug Patent Ruling

    The Federal Circuit didn't seem all too convinced Tuesday morning that a lower court committed an error in finding that healthcare company Fresenius Kabi USA had failed to prove that a pair of Heron Therapeutics patents covering a nausea drug were invalid.

  • November 03, 2026

    Mallinckrodt Loses $9.5M Award, Wins Delay In Airgas Drug

    A Delaware federal judge on Tuesday threw out Mallinckrodt Pharmaceuticals' $9.5 million jury award it won in an infringement case and instead blocked a competitor's inhaled nitric oxide treatment patent until after a pair of Mallinckrodt's patents expire.

  • November 03, 2026

    Chancery Ends Icahn Suit Over Illumina's $8B Grail Deal

    The Delaware Chancery Court has approved the dismissal of a lawsuit brought by affiliates of activist investor Carl Icahn against Illumina Inc.'s former directors over the biotechnology company's $8 billion acquisition of Grail Inc., ending the case under a settlement that does not bind other stockholders.

  • November 03, 2026

    Ex-Employee Calls J&J Unit's Trade Secret Suit Retaliation

    A former associate director sued by a Johnson & Johnson subsidiary for allegedly misappropriating confidential information hit back with her own complaint, alleging the company's lawsuit is retaliation for reporting discriminatory and retaliatory conduct by her manager.

Expert Analysis

  • 2nd Circ. EFAA Ruling Shifts Employer Litigation Strategy

    Author Photo

    In Diaz-Roa v. Hermes Law, the Second Circuit recently held that, under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act, employers can't carve out nonharassment claims and send them to arbitration, which has implications for discovery, litigation costs and resolution strategy in EFAA-covered disputes, say attorneys at Krevolin Horst.

  • 3rd Circ. Ruling Opens Door For Fraud-On-The-Market Rethink

    Author Photo

    The Third Circuit's recent decision in Ocugen, holding that a stable stock price after publication of restated financials does not prove immateriality, could be a vehicle for the U.S. Supreme Court to overturn the doctrine undergirding certification of securities class actions, says Jonathan Richman at Brown Rudnick.

  • 5 Issues To Watch As Fed. Circ. Hears Moderna Vax IP Case

    Author Photo

    Upcoming oral arguments before the Federal Circuit in Arbutus v. Moderna will test whether patent liability protections for government contractors extend to vaccines distributed to the public, and the resolution of certain questions, such as how to define “for the government,” may be key to the outcome, say attorneys at Honigman.

  • 6 Ways Biotechs Can Manage Double Patenting Rejection Risk

    Author Photo

    The Patent Trial and Appeal Board review panel’s recent rejection of a Sanofi application signals that biotechnology and pharmaceutical companies should now take steps to mitigate the possibility that their patents may be rejected for obviousness-type double patenting based on the existence of applications filed years later, say attorneys at Sterne Kessler.

  • Series

    Being In The Peace Corps Made Me A Better Lawyer

    Author Photo

    When I served in the Peace Corps, the people of the West African village where I was stationed helped me acclimate to my new surroundings and enabled me to develop problem-solving, teamwork and empathy skills that have bolstered my legal practice far beyond the ability to offer technical advice, says Brian Bewley at McGuireWoods.

  • 6th Circ. Spotlights Cannabis Contract Enforceability Risks

    Author Photo

    The Sixth Circuit's recent reversal of a $31.8 million jury verdict against a subsidiary of cannabis giant Curaleaf highlights that state licenses do not necessarily provide the legal foundation needed to enforce contracts in federal court, which is a pattern that appears across many sectors, say attorneys at ArentFox Schiff.

  • Where DOJ's Fraud Directive May Actually Affect Enforcement

    Author Photo

    The U.S. Department of Justice’s recent directive outlining corporate fraud enforcement priorities is mostly a management document instead of a policy, but one part may actually undermine the directive's goals by leading to worse outcomes for organizational defendants and less corporate self-disclosure, says Zachary Warren at Williams & Connolly.

  • Why Vaccine Court Inoculates Drugmakers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

  • Data Sale In Spirit Bankruptcy Raises Novel Privacy Risks

    Author Photo

    Spirit Airlines' planned sale of deidentified business data to Google for artificial intelligence training exposes gaps in the Bankruptcy Code's privacy guardrails, particularly for employee information, say attorneys at Patterson Belknap.

  • IDScan Data Breach Puts Spotlight On Vendor Oversight

    Author Photo

    A recently reported breach that exposed millions of identification documents held by IDScan.net highlights the liability risks for businesses that contract with third-party identity processors, and emphasizes the importance of auditing vendors' data retention practices, say attorneys at Tucker Ellis.

  • Series

    Mentalism Makes Me A Better Lawyer

    Author Photo

    Convincing strangers I can read their minds may seem like an unusual second career for a legal practitioner, but both disciplines share several important requirements, including trust and preparation, says Warren Biro at Manatt.

  • Why And How To Build A Neurodiversity-Informed Practice

    Author Photo

    By better understanding neurodiversity and implementing simple accommodations for clients with autism, ADHD or learning differences, attorneys can build stronger relationships with those who may otherwise struggle to obtain and benefit from legal services, while developing good habits that will benefit everyone they represent, says Ting Cheung at Sanford Heisler.

  • Opinion

    PTAB Panels Should Revamp Their IPR Merits Decisions

    Author Photo

    In light of U.S. Patent and Trademark Office Director John Squires' recent announcement about returning merits institution determinations to the Patent Trial and Appeal Board, the implementing framework should strengthen PTAB panels' responsibility for the benefit of both petitioners and patent owners, says Brandon Theiss at AddyHart.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.